	US 12,268,707 B2
	Treatment for coronavirus infection and associated cytokine toxicity
Sydney David Cullis-Hill, Bondi Junction (AU)
Appl. No. 17/910,220
Filed by Sydney David Cullis-Hill, Bondi Junction (AU)
PCT Filed Mar. 12, 2021, PCT No. PCT/AU2021/050215 § 371(c)(1), (2) Date Sep. 8, 2022, PCT Pub. No. WO2021/179047, PCT Pub. Date Sep. 16, 2021.
Claims priority of application No. 2020900751 (AU), filed on Mar. 12, 2020; and application No. 2020904824 (AU), filed on Dec. 23, 2020.
Prior Publication US 2023/0120864 A1, Apr. 20, 2023
Int. Cl. A61K 31/737 (2006.01); A61K 45/06 (2006.01); A61P 31/14 (2006.01)

CPC A61K 31/737 (2013.01) [A61K 45/06 (2013.01); A61P 31/14 (2018.01)]

34 Claims

1. A method of treating or preventing coronavirus infection or a disease or condition caused by or associated with coronavirus infection, the method comprising

administering to an individual suspected of having, or of having had a coronavirus infection, a therapeutically effective amount of pentosan polysufate (PPS) or a pharmaceutically acceptable salt thereof;

thereby treating or preventing coronavirus infection or a disease or condition caused by or associated with coronavirus infection in the individual.